

References

I-137

1. Pott C, Belada D, Danesi N, et al. Analysis of minimal residual disease in follicular lymphoma patients in gadolin, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-hodgkin lymphoma. *Blood*. 2015;126(23),3978.
2. MICROMEDEX®SOLUTIONS Compendia. 2020. Obinutuzumab.
3. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Obinutuzumab.
4. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. *N Engl J Med*. 2017;1331-44.
5. Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. *J Clin Oncol*. 2017;3529-3537.
6. Grigg A, Dyer MJS, Diaz MG, et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. *Haematologica*. 2017;765-772.
7. Raedler LA. Gazyva (Obinutuzumab) approved as first-line treatment, with chemotherapy, for patients with follicular lymphoma. *American Health & Drug Benefits*. 2018;11:64-66.
8. Dhillon S. Obinutuzumab: A review in rituximab-refractory or -relapsed follicular lymphoma. *Targeted Oncology*. 2017;12(2):255-262.
9. Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study. *Journal of Clinical Oncology*. 2018;36(22):2259-2266.
10. Gazyva® (obinutuzumab), for injection [package insert]. Genentech, Inc. South San Francisco, CA. Revised 11/2017.
11. National Comprehensive Cancer Network (NCCN). Obinutuzumab. NCCN Drugs and Biologics Compendium®. 2020.